

# Franklin Future Of Health And Wellness UCITS ETF



Thematic IE0003WEWAX4 Factsheet as of 30 April 2024

This is a marketing communication. Please refer to the prospectus of the UCITS and to the KID/KIID before making any final investment decisions.

### Investment Overview

The objective of the Fund is to provide exposure to companies that are involved in delivering sustainable products and services related to health and wellness globally. The Fund seeks to track the performance of the Solactive Sustainable Health and Wellness Index (the “Index”) as closely as possible, regardless of whether the Index level rises or falls, while seeking to minimise as far as possible the tracking error between the Fund's performance and that of the Index. The Index is comprised of global equity securities issued by companies from developed markets and is designed to measure the equity performance of those companies that are utilising technology and demonstrating innovation within the healthcare industry as well as companies that are enabling access to care, health, or wellness provision for a wide range of consumers including the elderly.

### Performance

Under current legislation, we are not allowed to display performance data with less than a complete 12 month performance record.

### Fund Overview

Fund Base Currency	USD
Fund Inception Date	05/07/2023
Bloomberg	FOHW GY
Valor Number	127057322
ISIN	IE0003WEWAX4
Domicile	Ireland
UCITS	Yes
Product Structure	Physical
Replication Methodology	Full Replication
Frequency of Index	
Reconstitution	Semiannually
Use of Income	Accumulation
Fiscal Year End	30 June
Shares Outstanding	100,000
EU SFDR Category	Article 8

### Benchmark(s) and Type

Solactive Sustainable Health and Wellness Index-NR	Target
--	--------

### Charges

Total Expense Ratio	0.30%
---------------------	-------

The charges are the fees the Fund charges to investors to cover the costs of running the Fund. Additional costs, including transaction fees, will also be incurred. These costs are paid out by the Fund, which will impact on the overall return of the Fund. Fund charges will be incurred in multiple currencies, meaning that payments may increase or decrease as a result of currency exchange fluctuations.

### Fund Characteristics

	Fund	Target
Total Net Assets	\$2.52 Million	
Number of Holdings	90	90
Price to Book	3.54x	4.12x
Price to Earnings (12-Month Trailing)	27.26x	28.88x
Return on Equity	14.23%	14.23%
Dividend Yield	1.32%	1.32%

Top Equity Issuers (% of Total)

	Fund
ASTRAZENECA PLC	3.92
ELI LILLY & CO	3.56
NOVO NORDISK A/S	3.52
MERCK & CO INC	3.31
ABBOTT LABORATORIES	3.12
THERMO FISHER SCIENTIFIC INC	3.02
ABBVIE INC	2.87
INTUITIVE SURGICAL INC	2.73
ROCHE HOLDING AG	2.56
PFIZER INC	2.56

Geographic Allocation (% of Total)

	Fund	Target
United States	67.11	68.37
Switzerland	5.55	5.55
Denmark	5.16	5.17
France	4.63	4.64
United Kingdom	4.60	4.60
Germany	4.29	3.64
Australia	3.04	2.58
Japan	2.37	2.37
Other	3.13	3.07
Cash & Cash Equivalents	0.13	0.00

Sector Allocation (% of Total)

	Fund
Health Care Equipment	30.31
Pharmaceuticals	25.37
Biotechnology	12.20
Life Sciences Tools & Services	6.30
Health Care Facilities	4.80
Personal Products	2.27
Managed Health Care	2.26
Health Care Services	2.23
Other	14.13
Cash & Cash Equivalents	0.13

Market Cap Breakdown (% of Equity) (USD)

	Fund
<2.0 Billion	9.67
2.0-5.0 Billion	8.15
5.0-10.0 Billion	5.49
10.0-25.0 Billion	9.62
25.0-50.0 Billion	10.73
>50.0 Billion	56.34

Trading Information

Exchange	Ticker	Currency	Bloomberg	Reuters	SEDOL
Borsa Italiana	FOHW	EUR	FOHW IM	FOHW.MI	BMCJZ47
Deutsche Börse Xetra	FOHW	EUR	FOHW GR	FOHW.DE	BMCJZ36
London Stock Exchange	FRHW	GBP	FRHW LN	FRHW.L	BMCJZ81
London Stock Exchange	FOHW	USD	FOHW LN	FOHW.L	BMCJZ70
SIX Swiss Exchange	FOHW	USD	FOHW SW	FOHW.S	BMCJZ58

Portfolio Management

	Years with Firm	Years of Experience
Lorenzo Crosato, CFA	6	25
Dina Ting, CFA	8	28

What are the Risks?

The Fund does not offer any capital guarantee or protection and you may not get back the amount invested. The Fund is subject to the following risks which are materially relevant: **Concentration risk:** the risk that arises when a fund invests in relatively few holdings, few sectors or a restricted geographic area. Performance may be more volatile than a fund with a greater number of securities. **Counterparty risk:** the risk of failure of financial institutions or agents (when serving as a counterparty to financial contracts) to perform their obligations, whether due to insolvency, bankruptcy or other causes. **Derivative Instruments risk:** the risk of loss in an instrument where a small change in the value of the underlying investment may have a larger impact on the value of such instrument. Derivatives may involve additional liquidity, credit and counterparty risks. **Foreign Currency risk:** the risk of loss arising from exchange-rate fluctuations or due to exchange control regulations. **Index related risk:** the risk that quantitative techniques used in creating the Index the Fund seeks to track do not generate the intended result, or that the portfolio of the Fund deviates from its Index composition or performance. **Secondary market trading risk:** the risk that the shares purchased on the secondary market cannot usually be sold directly back to the Fund and that investors may therefore pay more than the NAV per share when buying shares or may receive less than the current NAV per Share when selling shares. Complete information on the risks of investing in the Fund are set out in the Fund's prospectus.

Glossary

**Target:** The benchmark is defined in the objective as a target the Fund intends to meet or beat. **Total Expense Ratio:** Total Expense Ratio (TER) includes the fees paid to the management company, the investment manager and the depository, as well as certain other expenses. The TER is calculated by taking the relevant main material costs paid out over the 12-month period indicated and dividing them by the average net assets over the same period. The TER does not include all expenses paid by the fund (for example, it does not include what the fund pays for buying and selling securities). For a comprehensive list of the types of costs deducted from fund assets, see the prospectus. For recent all-in annual costs, as well as hypothetical performance scenarios that show the effects that different levels of return could have on an investment in the fund, where applicable, see the KID/KIID. For funds that lack 12 months of data, or for which TER is not likely to give a fair idea of likely future costs, the figure shown is an estimate. **Product Structure:** The Product Structure indicates whether an ETF is holding physical securities (i.e. Physical) or whether it is tracking the index performance using derivatives (swaps, i.e. Synthetic). **Methodology:** The Methodology indicates whether an ETF is holding all index securities in the same weight as the index (i.e. Physical Replication) or whether an optimised subset of index securities is used (i.e. Optimised) in order to efficiently track index performance. **Price to Book:** The price per share of a stock divided by its book value (i.e., net worth) per share. For a portfolio, the value represents a weighted average of the stocks it holds. **Price to Earnings (12-Month Trailing)** is the share price of a stock, divided by its per-share earnings over the past year. For a portfolio, the value represents a weighted average of the stocks it holds. **Return on Equity:** A measure of a corporation's profitability that reveals how much profit a company generates with the money shareholders have invested. For a portfolio, the value represents a weighted average of the stocks it holds. **Dividend Yield** is the annual dividend received on an equity security as a percentage of the price. For a portfolio, the value represents a weighted average of the stocks it holds. It should not be used as an indication of the income received from this portfolio.

Portfolio Data Information

Holdings are provided for information purposes only and should not be deemed a recommendation to buy or sell the securities mentioned.

### Important Information

**This fund meets the requirements under Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR); the fund has binding commitments in its investment policy to promote environmental and/or social characteristics and any companies in which it invests should follow good governance practices.**

Further information in relation to the sustainability-related aspects of the Fund can be found at [www.franklintempleton.lu/SFDR](http://www.franklintempleton.lu/SFDR). Please review all of the Fund's objectives and characteristics before investing. This is a sub-fund ("Fund") of Franklin Templeton ICAV, an Irish collective asset-management vehicle. An investment in Franklin Templeton ICAV entails risks which are described in the latest prospectus or supplement and in the KID/KIID. The Fund's documents are available in English, German and French from your local website or can be requested via FT's European Facilities Service available at [www.eifs.lu/franklintempleton](http://www.eifs.lu/franklintempleton). In addition, a Summary of Investor Rights is available from [www.franklintempleton.lu/summary-of-investor-rights](http://www.franklintempleton.lu/summary-of-investor-rights). The summary is available in English. Franklin Templeton ICAV is notified for marketing in multiple EU Member States under the UCITS Directive. Franklin Templeton ICAV can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive. For the avoidance of doubt, if you decide to invest, you will be buying units/shares in the Fund and will not be investing directly in the underlying assets of the Fund.

Given the variety of investment options available today, we suggest investors seek guidance from a Financial Adviser.

**CFA®** and Chartered Financial Analyst® are trademarks owned by CFA Institute.

Solactive AG ("Solactive") is the licensor of (the "Index"). The financial instruments that are based on the Index are not sponsored, endorsed, promoted or sold by Solactive in any way and Solactive makes no express or implied representation, guarantee or assurance with regard to: (a) the advisability in investing in the financial instruments; (b) the quality, accuracy and/or completeness of the Index; and/or (c) the results obtained or to be obtained by any person or entity from the use of the Index. Solactive reserves the right to change the methods of calculation or publication with respect to the Index. Solactive shall not be liable for any damages suffered or incurred as a result of the use (or inability to use) of the Index.

Net Returns (NR) include income net of tax withholding when dividends are paid.

**In Europe** (excluding Switzerland), this financial promotion is issued by Franklin Templeton International Services S.à r.l. - Supervised by the Commission de Surveillance du Secteur Financier - 8A, rue Albert Borschette, L-1246 Luxembourg - Tel: +352-46 66 67-1 - Fax: +352-46 66 76. **In Switzerland**, issued by Franklin Templeton Switzerland Ltd, Stockerstrasse 38, CH-8002 Zurich. Paying agent in Switzerland is BNP Paribas Securities Services, Paris, succursale de Zurich, Selnastrasse 16, 8002 Zurich. **UK contact information**, UK Freephone: 0800 305 306 | email: [enquiries@franklintempleton.co.uk](mailto:enquiries@franklintempleton.co.uk) [www.franklintempleton.co.uk](http://www.franklintempleton.co.uk)